Qianhai Health Holdings Ltd. (0911) AI Stock Analysis

• Market Cap: HK$56.76M
• Dividend Yield: N/A
• Average Volume (3M): 100.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: -40.37%
• EPS Growth: -112.64%
• Country: HK
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.08
• Shares Outstanding: 169,445,000
• 10 Day Avg. Volume: 108,550
• 30 Day Avg. Volume: 100,886
• PEG Ratio: -0.30
• Price to Book (P/B): 0.13
• Price to Sales (P/S): 0.09
• P/FCF Ratio: 11.52
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: HK$0.50 ▲(66.67% Upside)

The overall stock score of 52 reflects a mixed outlook. The company's financial performance shows improvement but is overshadowed by cash flow issues and revenue volatility. Technical analysis indicates positive momentum, but valuation concerns due to a negative P/E ratio and lack of dividend yield weigh heavily on the score.

Qianhai Health Holdings Ltd. Business Overview & Revenue Model

Company Description

Qianhai Health Holdings Ltd. (0911) is a health and wellness company based in Hong Kong, primarily focused on the development and distribution of healthcare products and services. The company operates in various sectors, including traditional Chinese medicine, health supplements, and wellness services. Its core offerings include herbal products, vitamins, and dietary supplements, catering to the increasing demand for natural health solutions in the market.

How the Company Makes Money

Qianhai Health Holdings generates revenue through multiple streams, primarily from the sale of its health supplements and traditional Chinese medicine products. The company capitalizes on the growing consumer preference for health and wellness products, leveraging both online and offline sales channels. Additionally, Qianhai Health engages in strategic partnerships with healthcare providers and distributors to expand its market reach and enhance product visibility. The company also explores opportunities in e-commerce, aiming to increase direct sales to consumers through its online platforms, which has proven to be a significant contributor to its earnings.

Qianhai Health Holdings Ltd. Financial Statement Overview

Summary

Qianhai Health Holdings Ltd. shows signs of financial improvement with a return to profitability in 2024. However, significant revenue fluctuations and cash flow challenges highlight potential risks. The balance sheet remains strong with low debt levels, but the company must address its cash flow issues to ensure sustainable growth.

Income Statement

The company's revenue has shown significant volatility with a notable decline from 2022 to 2023. Despite this, the gross profit margin improved to 5.71% in 2024 from a negative margin in 2023. Net profit margins have improved from negative to a marginally positive 0.25% in 2024, indicating a turnaround. However, the negative revenue growth rate and fluctuating EBIT and EBITDA margins signal instability and potential risk.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 94.67% in 2024, suggesting financial stability and low leverage risk with a debt-to-equity ratio of only 0.0027. However, the overall decrease in total assets over the years could be a concern for future growth potential.

Cash Flow

The cash flow situation is concerning, as operating and free cash flows were zero in 2024, indicating potential liquidity issues. The company has previously experienced negative cash flows, which could affect its ability to invest and grow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	383.16M	519.70M	961.29M	1.96B	283.40M	760.72M
Gross Profit	-6.15M	29.67M	-35.60M	76.48M	16.04M	45.13M
EBITDA	1.78M	15.64M	-50.23M	-231.24M	2.06M	5.63M
Net Income	-11.85M	1.31M	-52.70M	-233.70M	-888.00K	-804.00K
Balance Sheet
Total Assets	392.38M	407.31M	478.12M	534.43M	738.63M	735.47M
Cash, Cash Equivalents and Short-Term Investments	27.43M	23.51M	19.52M	1.64M	2.47M	16.36M
Total Debt	733.00K	1.03M	487.00K	1.19M	7.83M	24.07M
Total Liabilities	2.32M	21.74M	94.00M	97.73M	68.09M	62.28M
Stockholders Equity	390.06M	385.57M	384.11M	436.70M	670.53M	673.19M
Cash Flow
Free Cash Flow	10.48M	4.19M	857.00K	-5.26M	-44.19M	-70.90M
Operating Cash Flow	10.48M	4.20M	857.00K	-5.26M	-44.18M	-70.89M
Investing Cash Flow	11.00K	246.00K	17.77M	12.34M	46.84M	122.43M
Financing Cash Flow	-340.00K	-712.00K	-743.00K	-7.91M	-16.56M	-55.19M

Qianhai Health Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0911, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.30, above the 50-day MA of 0.29, and above the 200-day MA of 0.25, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 63.53 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0911.

Qianhai Health Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8622	―	HK$275.26M	―	-8.71%	―	2.54%	33.33%
1652	―	HK$691.11M	―	-40.38%	―	-43.46%	-96.48%
0911	―	HK$56.76M	―	-2.40%	―	-40.37%	-112.64%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0858	―	HK$237.15M	1.00	23.02%	―	-6.21%	―
1498	―	HK$169.82M	―	-33.22%	―	-17.32%	55.74%
1312	―	HK$167.36M	―	-41.48%	―	6.55%	-475.22%

Qianhai Health Holdings Ltd. Corporate Events

Qianhai Health Holdings Reports Decline in Interim Profits for 2025

Qianhai Health Holdings Ltd. announced its unaudited interim results for the six months ending June 30, 2025. The company reported a decrease in gross profit from HK$42,896,000 in 2024 to HK$14,155,000 in 2025, despite an increase in revenue from HK$306,970,000 to HK$340,853,000. The decline in profit is attributed to increased costs of sales and administrative expenses. The earnings per share also dropped significantly from 9.18 cents to 2.82 cents, indicating a challenging period for the company.

The most recent analyst rating on (HK:0911) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Qianhai Health Holdings Ltd. stock, see the HK:0911 Stock Forecast page.

Qianhai Health Holdings to Review Interim Results and Dividend Proposal

Qianhai Health Holdings Ltd. has announced that its Board of Directors will meet on August 20, 2025, to review and approve the unaudited interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation for the payment of an interim dividend, which could impact shareholder returns and market perception.

Qianhai Health Holdings Issues Profit Warning Amid Market Challenges

Qianhai Health Holdings Ltd. has issued a profit warning, indicating a projected decrease in profit attributable to owners by approximately 60% to 70% for the first half of 2025 compared to the same period in 2024. This decline is attributed to lower selling prices of electronic components and higher costs, which have led to a reduction in gross profit and margin. The company is in the process of finalizing its unaudited consolidated results, which may be subject to adjustments, and advises caution for shareholders and potential investors.